Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 2 1

Status

Completed 2Withdrawn 1Terminated 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

NET 2Endocrine 2Gastrointestinal 1CNS 1

Conditions

Neuroendocrine Tumors 2Neuroblastoma 1Meningioma 1Medulloblastoma 1Gastro-enteropancreatic neuroendocrine tumor 1Carcinoid Tumor 1

Interventions

Cyclophosphamide 1499Cisplatin 1435Paclitaxel 1340Radiotherapy 1310Carboplatin 1267Gemcitabine 1226Docetaxel 1133Bevacizumab 1070Fluorouracil 906Doxorubicin 805Dexamethasone 755Rituximab 744Capecitabine 735Oxaliplatin 709pembrolizumab 700Etoposide 679Irinotecan 639Filgrastim 624Cytarabine 587Nivolumab 586Leucovorin 583Vincristine 517Cetuximab 479Prednisone 478Bortezomib 474Trastuzumab 468Erlotinib Hydrochloride 467Surveys and Questionnaires 460Methotrexate 444Lenalidomide 436

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × arginyllysine × Clear all
NCT04524442 2025-01-24

Post-Authorization Safety Study (PASS) of LysaKare® in Adult Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients

Advanced Accelerator Applications

Phase 4 Completed
42 enrolled 11 charts
EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Carcinoid Tumor, Neuroendocrine Tumors

NCT03273712 2023-02-09

Dosimetry-Guided, Peptide Receptor Radiotherapy (PRRT) With 90Y-DOTA- tyr3-Octreotide (90Y-DOTATOC)

University of Iowa

Phase 2 Completed
39 enrolled 9 charts
CNSEndocrineNET

Medulloblastoma, Meningioma, Neuroblastoma, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡